Akanda Corp (AKAN): Analyst Consensus Forecast

Corporate company logo of Akanda Corp (AKAN)

This price chart for Akanda (AKAN) illustrates the price action of an asset valued at 0.00. The business relies on alliances with European pharmacies and physicians to implement therapy. Akanda (AKAN) has established a closed-loop product delivery cycle from Lesotho to the EU, although regulation restricts its pricing power. Currently, due to legal disputes and market saturation, the firm is losing influence and resorting to dumping.

Price Target Chart: Akanda Corp (AKAN) for 04/28/2023 - 11/11/2026

Analytical breakdowns for Akanda Corporation (AKAN)

- stock value and consensus price forecast:
Stock Price akandacorp.com|AKAN - Price Target Chart
- stock exchange capitalization data:
Market Capitalization Akanda Corporation|AKAN - Enterprise Value
- balance sheet equity data:
Book Value per Share Akanda|AKAN - Company Book Value|Capitalization to Book Value Ratio akandacorp.com|AKAN - Aggregate Company Assets
- debt obligations and liquidity statistics:
Debt to Equity Ratio Akanda|AKAN - Long-Term Debt to Capital|Short-Term Debt to Capital Akanda Inc|AKAN - Company Debts|Debt to Net Assets Ratio Akanda Corporation|AKAN - Company Long-Term Debts|Company Current Liabilities Akanda|Immediate Liquidity akandacorp.com
- company profitability and valuation multiples indicators:
AKAN - Net Income|Expected Net Income Akanda|AKAN - P/E Multiple|Price to Expected Earnings Ratio Akanda Corp|AKAN - PEG Multiple|EV/EBITDA Multiple Akanda Corporation|AKAN - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Akanda|AKAN - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months akandacorp.com|AKAN - Earnings growth in current year|Earnings growth forecast for next year Akanda
Fundamental company analysis:akandacorp.com, AKAN
Manufactured products of Akanda Corporation

Akanda (AKAN) vertical integration of cannabis supplies to Europe under limited pricing control makes the stock price sensitive to any regulatory changes. The current value of 0.00 represents a weighted average expert assessment, and analyzing the market consensus forecast vector on GURU.Markets allows for tracking the dynamics of revised expectations, where the absence of sharp downgrades confirms the stability of the asset's fundamental valuations.

Competing companies

Analyst Consensus Forecast indivior.com (INDV)|Price Target Chart Collegium Pharmaceutical, Inc. COLL|Analyst Consensus Forecast Cronos Group Inc CRON|Tweed - Analyst Consensus Forecast|HITI - Analyst Consensus Forecast|auroramj.com (ACB) - Price Target Chart|Broker Consensus Forecast ACHV|Price Target Chart Skye Bioscience, Inc.|Broker Consensus Forecast ANEB (Anebulo Pharmaceuticals Inc)|Analyst Consensus Forecast INCR|Analyst Consensus Forecast nutriband.com (NTRB)|Price Target Chart Nasus Pharma NSRX|Fair Value Consensus IGC|MIRA Pharma - Analyst Consensus Forecast|Flora Growth Corp (FLGC) - Consensus Target|imcannabis.com (IMCC) - Price Target Chart|Average Forecast Price Adial Pharmaceuticals, Inc. (ADIL)|Consensus Target ARTL|ENSC: Fair Value Consensus|Analyst Consensus Forecast TTNP|GNLN: Forecast Levels Chart|Analyst Consensus Forecast INM (InMed Pharma)|Analyst Consensus Forecast Enveric Corp ENVB|BGXX - Price Target Chart|Fair Value Consensus HPCO (hempaccoinc.com)